| Vaccine description | |
|---|---|
| Target | Smallpox,Mpox |
| Vaccine type | Live virus |
| Clinical data | |
| Trade names | Acam2000 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category | |
| Routes of administration | Percutaneous injection[2] |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
ACAM2000 is asmallpox vaccine and an mpox vaccine manufactured byEmergent Biosolutions. It provides protection againstsmallpox for people determined to be at high risk for smallpox infection.[2][4] ACAM2000 is a live replicatingvaccinia virus vaccine.[5]
The Mpox vaccine is on theWorld Health Organization's List of Essential Medicines.[7]
ACAM2000 isindicated for active immunization against smallpox disease for individuals determined to be at high risk for smallpox infection.[2][4][5] It is also indicated for the active prevention ofmpox disease in individuals determined to be at high risk for mpox infection.[5]
ACAM2000 is a vaccine developed by Acambis, which was acquired by Sanofi Pasteur in 2008, before selling the smallpox vaccine to Emergent Biosolutions in 2017. Six strains ofvaccinia were isolated from 3,000 doses of Dryvax and found to exhibit significant variation in virulence. The strain with the most similar virulence to the overall Dryvax mixture was selected and grown inMRC-5 cells to make the ACAM1000 vaccine. After a successful Phase I trial of ACAM1000, the virus was passaged three times inVero cells to develop ACAM2000, which entered mass production atBaxter. The United States ordered over 200 million doses of ACAM2000 in 1999–2001 for its stockpile, and production is ongoing to replace expired vaccine.[8][9]
Emergent Biosolutions developed ACAM2000 under a contract with the USCenters for Disease Control and Prevention (CDC).[10]
The USFood and Drug Administration (FDA) approved ACAM2000 in August 2007.[2][4] By February 2008, it replaced Dryvax for all smallpox vaccinations.[11]
As of 2010, there were over 200 million doses manufactured for the USStrategic National Stockpile.[11]
According to the US FDA, "The approval and availability of this second-generation smallpox vaccine in the Strategic National Stockpile (SNS) enhances the emergency preparedness of the United States against the use of smallpox as a dangerousbiological weapon."[12]
In August 2024, ACAM2000 was approved for mpox prevention in the United States.[13]
The ACAM2000 vaccine is produced from thevaccinia virus, which is sufficiently closely related to smallpox to provide immunity, but the ACAM2000 vaccine cannot cause smallpox because it does not contain the smallpox virus.[12] Other vaccines containing live viruses includemeasles,mumps,rubella,polio andchickenpox.[14]
The vaccine is administered using abifurcated stainless steel needle. The needle is dipped into the vaccine solution and used to prick the skin several times in the upper arm. The vaccinia virus will begin to grow at the injection site. It will cause a localized infection, with a red itchy sore produced at the vaccination site within three to four days. If the infection occurs, that is an indication that the vaccine was successful. Ultimately, the sore turns into a blister and then dries up. A scab forms and then falls off in the third week, leaving a small scar behind.[12]
Administration of ACAM2000 poses risks and may cause side effects. Most people who have taken the vaccine only report mild reactions. Reactions may include a sore arm, fever, and body aches. Some people may have more serious side effects, including effects that may be life-threatening.[15]
According to the FDA-approved prescribing information leaflet, "Common adverse events include inoculation site signs and symptoms, lymphadenitis, and constitutional symptoms, such as malaise, fatigue, fever, myalgia, and headache."[2] These reactions are less frequent in people being revaccinated than those receiving the vaccine for the first time.[2]
No known contraindications exist to receiving the vaccine in case of an outbreak emergency. Furthermore, it is recommended that the vaccine should be given to pregnant women who have been exposed to smallpox. "Because the risk of maternal serious illness or death, prematurity, miscarriage, or stillbirth from a smallpox infection are greater than the risk of the vaccination, smallpox vaccine is recommended and should be offered to pregnant women in case of an outbreak emergency."[16]
{{cite web}}:Missing or empty|title= (help)
This article incorporates text from this source, which is in thepublic domain.
